世界卫生组织药物信息-第40卷第1号

Volume40 Number1 2026 Recommended INN: List 95International Nonproprietary Names for Pharmaceutical Substances WHO Drug Information WHO Drug Information provides an overview of topics relating to medicines development, regulation, quality and safety. The journalalso publishes and reports on guidance documents and includes lists of International Nonproprietary Names for PharmaceuticalSubstances (INN), ATC/DDD classification and monographs for The International Pharmacopoeia. It presents and describes WHOpolicies and activities while reflecting on technical and pharmaceutical topics of international and regional interest. WHO Drug Information is published four times a year and can be ordered from:WHO Press, World Health Organization, 1211 Geneva 27, Switzerland.e-mail:bookorders@who.intor on line athttp://www.who.int/bookorders WHO Drug Information can be viewed at:https://www.who.int/our-work/access-to-medicines-and-health-products/who-drug-information WHO Drug Information, Vol. 40, No. 1, 2026 ISBN978-92-4-012196-6(electronic version)ISBN978-92-4-012197-3(print version)ISSN 1010-9609 © World Health Organization 2026 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence(CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work isappropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specificorganization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your workunder the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimeralong with the suggested citation:“This translation was not created by the World Health Organization (WHO). WHO is not responsible forthe content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the WorldIntellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/). Suggested citation. WHO Drug Information, Vol. 40, No. 1, 2026. Geneva: World Health Organization; 2026. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.CIP data are available at https://iris.who.int/. Sales, rights and licensing.To purchase WHO publications, see https://www.who.int/publications/book-orders. To submit requests forcommercial use and queries on rights and licensing, see https://www.who.int/copyright. Third-party materials.If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images,it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder.The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user. General disclaimers.The designations employed and the presentation of the material in this publication do not imply the expression ofany opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, orconcerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines forwhich there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended byWHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietaryproducts are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the publishedmaterial is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and useof the material lies with the reader. In no event shall WHO be liable for damages arising from its use. WHO Drug Information Contents Consultation Documents 01Dapsone (dapsonum)08Dapsone Tablets (dapsoni compressi) International Nonproprietary Names (INN)15Recommended INN List No. 95 Abbreviations and websites CHMPCommittee for Medicinal Products for Human Use(https://www.ema.europa.eu/en/committees/committee-medicinal-products-human-use-chmp)EMAEuropean Medicines Agency (www.ema.europa.eu)EUEuropean Union (https://european-union.europa.eu/index_en)FDAU.S. Food and Drug Administration (www.fda.gov)Health CanadaFederal department responsible for health product regulation in Canada (www.hc-sc.gc.ca)HPRAHSAICDRAICHIGDRPINNMHLWMHRAMedsafePh. IntPMDASwissmedicTGAWHOWHO MHPWHO RPQWHO PQTWHO HPSHe